High serum phosphate concentration as the result of smoking might underlie the lower risk of Parkinson’s disease

Håglin, Lena

doi:10.1016/j.mehy.2015.05.017

Cited by 2 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the role of C-terminal FGF-23 under these conditions is poorly understood. Interestingly, epidemiological studies have shown a negative association between smoking and Parkinson's disease,12 so that smokers had higher serum P and had a lower risk of the disease. Higher P levels were also observed in men and women with diabetes, even after adjusting for age and other cardiovascular risk factors 13.…”

Section: Discussionmentioning

confidence: 99%

Chronic kidney disease patients who smoke have higher serum phosphorus

et al. 2019

View full text Add to dashboard Cite

Introduction: Mineral and bone metabolism disorders in chronic kidney disease (CKD-MBD) constitute a syndrome defined by changes in calcium, phosphorus (P), vitamin D and parathormone, fibroblast growth factor 23 (FGF-23) and its specific cofactor, Klotho. CKD-MBD, as well as smoking, are associated with an increased risk of cardiovascular disease. However, it is not known whether or not smoking impacts the cardiovascular risk in CKD- MBD. Objective: To analyze the relationship between smoking and CKD-MBD markers. Methods: We evaluated 92 patients divided into: 1) Control Group: non-smokers without CKD; 2) CKD group in stages III and IV under conservative treatment (20 non-smokers and 17 smokers); 3) CKD group on dialysis (21 non-smokers and 19 smokers). Clinical, demographic, and biochemical markers were compared between the groups. Results: FGF-23 and Klotho levels were not different between smokers and non-smokers. Patients in the CKD group on conservative treatment had higher serum P than non-smokers (p = 0.026) even after adjusted for renal function (p = 0.079), gender (p = 0.145) and age (p = 0.986). Conclusion: Smoking confers a higher cardiovascular risk to CKD patients under conservative treatment as it is associated with higher levels of P. Further studies are needed to confirm and better elucidate this finding.

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic kidney disease patients who smoke have higher serum phosphorus

et al. 2019

View full text Add to dashboard Cite

show abstract

Assessment of Serum Levels of Phosphate and Corticosterone as Possible Biomarkers for Early Diagnosis of Parkinson’s Disease in Rats with 6-OHDA-Induced Parkinson

Haghdoost-Yazdi,

Nigjeh,

Hosseini

et al. 2024

Journal of Kerman University of Medical Sciences

View full text Add to dashboard Cite

Background: Early diagnosis of Parkinson›s disease can play an important role in improving its prognosis. Due to controversies about the serum level of corticosterone and phosphate in parkinsonian rats, this study was designed to measure and evaluate the levels of corticosterone and phosphate as possible biomarkers of early diagnosis in rats with 6-OHDA-induced parkinsonism. Methods: Forty rats were divided into three groups: control (n=10), sham (n=10), and 6-OHDA (n=20). The rats in the 6-OHDA and sham groups underwent stereotaxic surgery to be injected with 6-OHDA and its carrier into their medial forebrain bundle (MFB). Apomorphine-induced rotational and cylinder tests were done to examine parkinsonism progression and sensory-motor function. Corticosterone and phosphate serum levels were measured in the serum and striatum. Results: Net contralateral rotations and asymmetry scores in the fourth, sixth, and eighth weeks after surgery compared with the second week showed a gradual increase in the 6-OHDA group. The serum levels of corticosterone were 90±13 before surgery, and they declined to 88±36 and 55±9 ng/L in the second and eighth weeks after surgery, respectively. The serum levels of phosphate were 6±0.22 before surgery, and they decreased to 5.2±0.13 and 5±0.12 mg/dl in the second and eighth weeks after surgery, respectively. The serum levels of phosphate and corticosterone remained relatively unchanged in the sham and control groups. Conclusion: In conclusion, the progressive death of dopaminergic neurons is accompanied by decreased serum corticosterone and phosphate levels. Thus, the serum level of corticosterone can be used as a biomarker in diagnosing Parkinson’s disease. In contrast, serum phosphate levels were still within the normal range and cannot be used as a biomarker.

show abstract

High serum phosphate concentration as the result of smoking might underlie the lower risk of Parkinson’s disease

Cited by 2 publications

References 39 publications

Chronic kidney disease patients who smoke have higher serum phosphorus

Chronic kidney disease patients who smoke have higher serum phosphorus

Assessment of Serum Levels of Phosphate and Corticosterone as Possible Biomarkers for Early Diagnosis of Parkinson’s Disease in Rats with 6-OHDA-Induced Parkinson

Contact Info

Product

Resources

About